Penicillamine has been used in the treatment of patients with rheumatoid arthritis with variable clinical response (Jaffe, 1963; Camus, Guillien, Crouzet, Schaeffer, and Lievre, 1970; Zuckner, Ramsey, Dorner, and Gantner, 1970; Golding, Wilson, and Day, 1970) . Moreover, observations on the effect of this drug on serum immunoglobulins and rheumatoid factor titres have yielded conflicting and indefinite results (Jaffe, 1970) . Currently, a U.K. multi-centre, double-blind, controlled trial is under way in which D-penicillamine is being compared to a placebo amongst patients with definite or classical rheumatoid arthritis (Camp, 1971) . A definitive paper reporting that trial will include detailed results of changes in rheumatoid factor titres measured in another laboratory. The present study reports the effect of the active drug versus placebo on the serum immunoglobulins and rheumatoid factor titres over a 6-month period in a group of patients entered into the current trial.
Material and methods

PATIENT GROUP
Sera from patients were obtained immediately before therapy and approximately 3 and 6 months after continuous penicillamine or placebo treatment. Patients were coded so that all assays were performed without knowing whether a patient was on drug or placebo*. The dosage schedule was usually designed gradually to achieve oral doses of 1,500 mg. of active penicillamine per day by the 9th week of treatment, and to maintain that dose thereafter. However, one patient was still taking the lower initial dose at the 3-and 6-month intervals.
Serum immunoglobulin levels were determined by radial immunodiffusion in agar-antibody plates (Hyland Laboratories, Los Angeles, California). Normal values (±2 standard deviations) for adults in our laboratory were: IgG 1,090 mg. per 100 ml. (±490); IgA 190 mg. per 100 ml. (±140); IgM 130 mg. per 100 ml. (±90).
Tests for rheumatoid factor activity were performed after initial heat inactivation at 56°C. for 30 min.; activity was measured at 22°C. using latex particles coated with aggregated human gamma globulin and sheep red blood cells sensitized with rabbit gamma globulin. Heterophil antibody titres were determined using a 2 per cent. suspension of non-sensitized sheep erthrocytes. Known positive and negative controls were included in each assay. Latex-agglutination titres greater than 1:40 and nonheterophil sensitized sheep-cell titres greater than 1 :2 were considered abnormal. (Table I) The majority of patients in the trial showed hypergammaglobulinaemia with elevated levels of IgG, A, and M. Individual serum IgG levels in patients taking penicillamine were lower at 3 months, and by 6 months the change had reached statistical significance (Table II; P < 0 05). No such fall in serum IgG was apparent in placebo-treated patients. By chance, the patients treated with penicillamine had a higher mean pre-treatment level of IgG than the control group. This prevented a significant difference in IgG levels between the two groups at 6 months despite the definite fall in serum IgG amongst the drug-treated patients by that time (Table II) . There was no apparent effect of the drug on serum IgA levels (Table III) .
Results
Seruim immunoglobulins
Drug-treated patients had a marked reduction (P < 0 02) in serum IgM at 3 months, well sustained at 6 months in contrast to controls whose IgM levels did not fall (Table IV) . Comparison of the penicillamine group with the controls showed that there was group.bmj.com on July 5, 2017 -Published by http://ard.bmj.com/ Downloaded from Effect of D-penicillamine on serum immunoglobulins and rheumatoidfactor 51 Paired data analysis of IgM change within the penicillamine-treated group showed significant reduction at 3 months (t=3-2747; P<0-02) and at 6 months (t=3-3946; P<0-02). The difference between penicillamine-treated and control groups was significant at 3 months (t= -2-7338; P<O05) and at 6 months (t= -23928; P<0 05). test). There was a highly significant correlation between the decline in serum IgM levels and the fall in latex titre after 6 months of penicillamine treatment (Spearman rank correlation co-efficient, Ys = 0 897; P < 0-001 in a one-sided test Previous reports on the effect of penicillamine on serum immunoglobulins and rheumatoid factor have been variable. Most observers have detected a probable drug-induced diminution in the levels of serum IgG and IgM and in the titres of antiglobulin (Jaffe, 1963 (Jaffe, , 1970 Goldberg and Barnett, 1970) , although a recent study failed to confirm this (Zuckner and others, 1970) . However, no double-blind control trial adequately to study this effect on meaningful numbers of patients has previously been reported; nor has a selective effect of penicillamine on serum IgG and IgM been previously ascertained. Goldberg and Barnett (1970) noted a pronounced diminution of IgG and IgM in their patient with essential cryoglobulinaemia, with less effect on the level of IgA. In our patients a lack of drug effect on serum IgA levels was striking.
The mechanism by which penicillamine causes a reduction in serum immunoglobulins is unknown. In vitro the drug acts by disruption of interchain disulphide bonds of macroglobulins, although a variable effect of the drug on IgG and IgA has been noted (Virella and Lopes-Virella, 1970) . However, it is unlikely that the activity of this drug in vitro accounts for its effects in vivo, and it is probable that other, unknown, mechanisms lower serum immunoglobulin levels. The results of this study suggest that the immunosuppressive action of penicillamine is a central one-selecting those cells which produce only certain classes of heavy chain.
The relationship between drug dose and immunosuppression has been partly elucidated by this study. 
